Inspire Medical Systems, Inc. (NYSE:INSP) Receives Consensus Rating of "Moderate Buy" from Analysts

Shares of Inspire Medical Systems, Inc. (NYSE:INSP - Get Free Report) have received an average rating of "Moderate Buy" from the eleven ratings firms that are covering the firm, MarketBeat Ratings reports. Three equities research analysts have rated the stock with a hold recommendation and eight have given a buy recommendation to the company. The average 12-month price target among brokers that have updated their coverage on the stock in the last year is $228.82.

INSP has been the topic of several analyst reports. Truist Financial reduced their price target on shares of Inspire Medical Systems from $250.00 to $235.00 and set a "buy" rating on the stock in a research report on Tuesday. Stifel Nicolaus lowered their price target on Inspire Medical Systems from $200.00 to $190.00 and set a "hold" rating for the company in a report on Tuesday, January 21st. Royal Bank of Canada reaffirmed an "outperform" rating and issued a $260.00 price objective on shares of Inspire Medical Systems in a research note on Tuesday. Bank of America raised Inspire Medical Systems from a "neutral" rating to a "buy" rating and boosted their target price for the stock from $220.00 to $255.00 in a research note on Wednesday, November 20th. Finally, Wells Fargo & Company dropped their target price on shares of Inspire Medical Systems from $198.00 to $195.00 and set an "equal weight" rating for the company in a report on Tuesday.

Inspire Medical Systems Price Performance

INSP stock traded up $2.18 during midday trading on Friday, reaching $183.17. 1,485,540 shares of the company were exchanged, compared to its average volume of 623,494. Inspire Medical Systems has a one year low of $123.00 and a one year high of $257.40. The firm has a market capitalization of $5.49 billion, a price-to-earnings ratio of 171.18 and a beta of 1.32. The business has a 50-day moving average price of $189.57 and a two-hundred day moving average price of $190.98.

Inspire Medical Systems (NYSE:INSP - Get Free Report) last announced its quarterly earnings results on Monday, February 10th. The company reported $1.15 EPS for the quarter, beating analysts' consensus estimates of $0.74 by $0.41. Inspire Medical Systems had a net margin of 4.37% and a return on equity of 5.30%. As a group, analysts anticipate that Inspire Medical Systems will post 1.33 earnings per share for the current fiscal year.

Institutional Trading of Inspire Medical Systems

Institutional investors have recently modified their holdings of the business. Creative Planning lifted its holdings in Inspire Medical Systems by 12.4% in the second quarter. Creative Planning now owns 2,575 shares of the company's stock valued at $345,000 after buying an additional 284 shares during the period. Cetera Investment Advisers lifted its stake in shares of Inspire Medical Systems by 497.7% in the 2nd quarter. Cetera Investment Advisers now owns 17,512 shares of the company's stock valued at $2,344,000 after purchasing an additional 14,582 shares during the period. Handelsbanken Fonder AB boosted its position in shares of Inspire Medical Systems by 12.0% during the 3rd quarter. Handelsbanken Fonder AB now owns 8,400 shares of the company's stock valued at $1,773,000 after purchasing an additional 900 shares in the last quarter. GAMMA Investing LLC grew its stake in Inspire Medical Systems by 559.3% during the third quarter. GAMMA Investing LLC now owns 178 shares of the company's stock worth $38,000 after purchasing an additional 151 shares during the period. Finally, CWM LLC grew its stake in Inspire Medical Systems by 550.5% during the third quarter. CWM LLC now owns 8,105 shares of the company's stock worth $1,711,000 after purchasing an additional 6,859 shares during the period. Institutional investors own 94.91% of the company's stock.

About Inspire Medical Systems

Inspire Medical Systems, Inc, a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA.